• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    /C O R R E C T I O N -- Heng Ren Partners/

    11/11/25 5:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care
    Get the next $SVA alert in real time by email

    In the news release, Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment, issued Nov. 11, 2025 by Heng Ren Partners over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:

    Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment

    BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared by the board.

    Sinovac's stock has been halted from trading since 2019. As a result, Sinovac shareholders missed out on an extraordinary windfall from the success of its COVID-19 vaccine, CoronaVac, and its billions of dollars in sales during the pandemic due to the trading halt. In July 2025, the current Board paid a $55.00 dividend to shareholders as partial compensation for dividends that had not been paid during the trading halt.

    The board declared an additional $19.00 dividend per common share on June 17, 2025. The dividend was announced as part of the current board's effort to pay independent Sinovac shareholders dividends they did not receive but which had been paid to certain affiliates and insiders who were minority shareholders of Sinovac subsidiaries.

    More than four months later, Sinovac has failed to announce record and payment dates for the declared dividend.

    Sinovac's failure to provide an update on the promised dividend is especially surprising as both the current board and the SAIF-led consortium that is seeking to replace the current board campaigned on the promise to pay dividends to benefit Sinovac shareholders.

    "All of the decisionmakers with influence in the Sinovac saga – the board, insiders, and management – should understand and respect the wishes of independent shareholders," said Peter Halesworth, the founder of Boston, Massachusetts-based Heng Ren. "Independent shareholder support in favor of dividends is clear and overwhelming. The current board should set record and payment dates for the promised $19.00 dividend now."

    For more information about the "Sinovac Fairness" campaign led by Heng Ren, please see https://www.hengreninvestment.com for more details.

    Correction: An earlier version of this release included incorrect public media information.

    Cision View original content:https://www.prnewswire.com/news-releases/independent-sinovac-shareholders-express-strong-support-for-immediate-dividend-payment-302611288.html

    SOURCE Heng Ren Partners

    Get the next $SVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SVA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    /C O R R E C T I O N -- Heng Ren Partners/

    In the news release, Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment, issued Nov. 11, 2025 by Heng Ren Partners over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared b

    11/11/25 5:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment

    BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared by the board. Sinovac's stock has been halted from trading since 2019. As a result, Sinovac shareholders missed out on an extraordinary windfall from the success of its COVID-19 vaccine, CoronaVac, and its billions of dollars in sales during the pandemic due to the trading halt. In July 2025, the current Board paid a $55.00 dividend to shareholders as partial compensation for dividends that h

    11/11/25 5:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SINOVAC Announces Appointment of Independent Auditor

    Critical step in improving transparency and resuming trading on NASDAQ The Board of Directors and Management of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Audit Committee of the Board has approved the engagement of UHY LLP ("UHY") headquartered in the U.S. as its independent auditor and registered public accounting firm, effective today, October 24, 2025. UHY is a U.S. member of Urbach Hacker Young International Limited (UHY International), a UK company, and forms part of the international UHY network of legally independent accounting and consulting firms. As a matter of priority, UH

    10/24/25 10:30:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    SEC Filings

    View All

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    7/10/25 9:54:16 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    7/9/25 9:53:38 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    7/9/25 9:55:18 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Leadership Updates

    Live Leadership Updates

    View All

    SINOVAC Announces Appointment of Independent Auditor

    Critical step in improving transparency and resuming trading on NASDAQ The Board of Directors and Management of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Audit Committee of the Board has approved the engagement of UHY LLP ("UHY") headquartered in the U.S. as its independent auditor and registered public accounting firm, effective today, October 24, 2025. UHY is a U.S. member of Urbach Hacker Young International Limited (UHY International), a UK company, and forms part of the international UHY network of legally independent accounting and consulting firms. As a matter of priority, UH

    10/24/25 10:30:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders

    Special Meeting validly adjourned until the appropriate court makes a final decision on validity of the PIPE shares and will be reconvened SAIF and the Dissenting Investor Group's deceptive claims of a "continuation of the Special Meeting" and a pretend "Board" are fake and without legal basis Current Board remains the only valid board of directors of SINOVAC and will continue to govern the Company The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company") today issued the following update to set the record straight regarding the Special Meeting of Shareholders (the "Special Meeting"): The Special Meeting was validly adjourned by SINOVAC Chairman Chian

    7/11/25 4:21:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC

    Court denies Vivo Capital's petition for relief relating to shareholder votes and corporate governance, clearing another legal hurdle for distribution of the US$55.00 per common share special cash dividend Marks fourth unsuccessful legal attempt in deceptive and disparaging campaign by Advantech/Prime or Vivo Capital against current Board and its Chairman New reports from two leading independent proxy advisory firms, Glass Lewis and ISS, firmly recommend shareholders vote to KEEP the current Board chaired by Dr. Chiang Li The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced

    7/7/25 1:46:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Financials

    Live finance-specific insights

    View All

    /C O R R E C T I O N -- Heng Ren Partners/

    In the news release, Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment, issued Nov. 11, 2025 by Heng Ren Partners over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared b

    11/11/25 5:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Newly Elected Directors of Sinovac Hold the First Board Meeting

    Mr. Andrew Y. Yan elected Chairman of the Board New Board Unanimously Resolved to Explore Future Dividend Plans, Conduct Search for New Auditor for Resuming NASDAQ Trading, and Restore Stable Operations of the Company, Amongst Other Things Sinovac Biotech Ltd. (NASDAQ:SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the new Directors), held its first meeting today at the Company's headquar

    7/10/25 7:23:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment

    Special cash dividend is being paid to valid common shareholders who owned SINOVAC as of the close of business on July 7, 2025 Board will continue to prioritize dividend distributions according to its previously announced policy For any questions about the dividend payment process, shareholders should contact Dividend Information Agent D.F. King at [email protected] The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the previously declared US$55.00 per common share special cash dividend is in the process of being paid to valid shareholders who owned SINOVAC shares as of

    7/9/25 12:27:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

    SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    9/12/24 4:03:46 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

    SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    6/17/24 4:02:44 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Sinovac Biotech, Ltd. (Amendment)

    SC 13G/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    3/20/24 7:33:23 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care